The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Genital Herpes from to segmented by seven major markets. According to this research, the prevalent population of Genital Herpes was estimated to be 83, [7MM] in There are currently three FDA approved anti-viral therapies including Acyclovir, Famciclovir and Valacyclovir, which are being used for the treatment of Genital herpes in the United States.
However these drugs have shown to be effective in managing the Genital Herpes frequent recurrence and healing of lesions but they are not fully potent in clearing the underline HSV infection. Also these drugs are associated with certain toxicity and subsequently virus are developing resistance against the existing batch of antivirals highlighting the need of innovative drugs. Curative drugs and vaccines remains one of the major unmet medical need in this space. Detailed chapters for all of these marketed drugs along with late phase promising candidates like Pritelivir and GEN have been covered in the report.
The dynamics of Genital Herpes market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period Launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed prevalent population of Genital Herpes.
Upcoming therapies such as Pritelivir Aicuris and GEN Genoceahave the potential to create a significant positive shift in the Genital Herpes market size. The market size of Genital Herpes includes the drug-uptake for individual therapies, which is further segmented on the basis of market size and market share by Line of therapy and Route of Administration.
To counter current unmet needs of the market and to provide better treatment options for Genital Herpes, several companies are working robustly on developing new therapies with novel mechanism of action. Drug Chapters There are currently three FDA approved anti-viral therapies including Acyclovir, Famciclovir and Valacyclovir, which are being used for the treatment of Genital herpes in the United States.
Drugs Uptake The market size of Genital Herpes includes the drug-uptake for individual therapies, which is further segmented on the basis of market size and market share by Line of therapy and Route of Administration.
Organize sales and marketing efforts by identifying the best opportunities for Genital Herpes market. To understand the future market competition in the Genital Herpes market. Contacts ResearchAndMarkets. Log In Sign Up.Herpes simplex virus type 1 HSV-1 and type 2 HSV-2 infections lead to lifelong persistence of the virus, with frequent and sometimes painful recurrences. In immunocompromised patients, HSV can lead to serious complications. In the immune competent, the negative stigma associated with genital herpes and visible facial lesions causes psychological distress.
Since the introduction of the nucleoside analogs decades ago, treatment of HSV infections has remained essentially unchanged. Current therapies for herpes infections fail to adequately reduce the number of HSV episodes, or to fully block transmission. Furthermore, they are associated with slow lesion healing and may be ineffective if initiated too late. Pritelivir belongs to a new chemical class and acts via a novel mechanism of action inhibition of the viral helicase-primase enzyme complex.
Due to this novel mechanism of action, and in contrast to the currently used nucleoside analogues, pritelivir does not require activation by viral enzymes and can thus protect uninfected cells. Pritelivir is active against herpes virus strains and retains activity against viruses which have become resistant to current standard drugs.
In Phase 2 clinical trials, Pritelivir has shown superiority over the market standard treatment valacyclovir. Pritelivir is currently in a Phase 2 clinical trial for immunocompromised patients with acyclovir-resistant infection. AiCuris supports the need for Early Access to Pritelivir oral tablets via single patient expanded access.
For more details please go here. In addition, AiCuris is working on a preclinical project for its use in vaginal rings as suppressive therapy. Toggle navigation.
Genital Herpes Market Insights, Epidemiology and Market Forecasts, 2018-2028
If you have further questions regarding partnering of our projects please contact:.Skip to main content. Published: Nov 12, Wuppertal, Germany, November 12, - AiCuris Anti-infective Cures GmbH today provided a strategic update, outlining its recent achievements and plans for future growth.
AiCuris specializes in the discovery, research and development of novel resistance-breaking antiviral and antibacterial agents for the treatment of serious, often life-threatening infectious diseases, and is one of the few biotech companies to see its drug brought to market and thereby to patients.
This work has earned the Company and its founders several high-profile awards, including the coveted German Future Prize. We are excited about this important work we are also doing in partnership with others and look forward to advancing programs that have the potential to cure patients and address major unmet medical needs. HCMV infection is one of the most dangerous complications following bone marrow transplantation.
AiCuris Provides Corporate Update - November 12, 2019
MSD for further development and commercialization. Letermovir might also be useful in other HCMV indications and is currently being developed for additional indications in solid organ transplantation, a pivotal study for the prophylactic treatment of HCMV in kidney transplant recipients is ongoing. AiCuris' mission is to develop innovative drugs against severe and life-threatening infectious diseases with high medical need. Development is focused on indications for which there are either no therapeutic options or for which available therapies are not effectively addressing the disease.
AiCuris develops its projects up to proof-of-concept and then follows a selective out-licensing strategy. To further expand its portfolio, AiCuris has entered into a number of collaboration agreements and strategic alliances and will continue to do so.
Internal development program Pritelivir — Phase 2 trial ongoing, AiCuris to conduct Phase 3 pivotal trial in Acyclovir resistant HSV infections in immunocompromised patients. Pritelivir belongs to a new chemical class and acts via a novel mechanism of action. In contrast to currently used nucleoside analogues, Pritelivir does not require activation by viral enzymes and can thus protect uninfected cells.
Pritelivir also retains activity against viruses which have become resistant to current standard of care drugs. Pritelivir has demonstrated superior efficacy in a Phase 2 trial compared to the standard treatment, valaciclovir, and is currently in another Phase 2 trial in immunocompromised patients with acyclovir-resistant infection.
AIC is a novel biological immunomodulator being developed for the curative treatment of chronic hepatitis B virus infections.
Results from a successfully completed Phase 1 study showed that a single intravenous dose of AIC was safe and well tolerated; there were no dose-limiting toxicities and the maximum tolerated dose was not reached. Despite the heterogeneity of the patients in the trial, there was evidence that a single dose of AIC stimulated the immune system. Earlier preclinical results in a chronic hepatitis B model indicated that treatment with AIC in combination with standard treatment entecavir could lead to functional cure.
Given the large size of the market, AiCuris is looking for a partner for the further development and commercialization of AIC to maximize the opportunity for this exciting product candidate.
Antibacterial agents - AiCuris is fighting multidrug-resistant bacteria in cooperation with Lysando.Dublin, Feb.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Genital Herpes from to segmented by seven major markets. Genital Herpes Epidemiology The Genital Herpes epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
This part of The report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken. The disease epidemiology covered in the report is segmented by prevalent population, gender-specific prevalent population and diagnosed cases of Genital Herpes.
The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight. According to this research, the prevalent population of Genital Herpes was estimated to be 83, [7MM] in However these drugs have shown to be effective in managing the Genital Herpes frequent recurrence and healing of lesions but they are not fully potent in clearing the underline HSV infection.
Also these drugs are associated with certain toxicity and subsequently virus are developing resistance against the existing batch of antivirals highlighting the need of innovative drugs. Curative drugs and vaccines remains one of the major unmet medical need in this space. Detailed chapters for all of these marketed drugs along with late phase promising candidates like Pritelivir and GEN have been covered in the report. Genital Herpes Market Outlook The dynamics of Genital Herpes market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period Launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed prevalent population of Genital Herpes.
Upcoming therapies such as Pritelivir Aicuris and GEN Genoceahave the potential to create a significant positive shift in the Genital Herpes market size. Market Drivers Market Barriers Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. Subscribe via RSS. Subscribe via ATOM.
Register Sign In. Email Print Friendly Share. Research and Markets. With a Reader Account, it's easy to send email directly to the contact for this release.The First Product to Cure the Herpes Virus. The Revolution to end Herpes is here
Sign up today for your free Reader Account! Already have an account? Log in here. Formats available: Original Medium Small. GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.One segment of the HSV infections report encloses the detailed analysis of marketed drugs and late stage pipeline drugs.
It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The current HSV Virus infections market is dependent on antiviral drugs that are not the cure of the disease but relief the symptoms of the disease and in long-term reduces the incidence of relapses if started before exposure to the triggering conditions. Although, antiviral therapies have proven its effectiveness in this market associated complications and need of a cure demands the emergence of novel therapy. The HSV Infections market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
Office Hours Call For U.
Herpes Simplex Market Insight, Epidemiology & Forecast to 2027 - ResearchAndMarkets.com
Key Insights 2. Epidemiology and Patient Population 5. Key Findings 6. Treatment Algorithm 8. Unmet needs 9. Marketed drugs Emerging Therapies Key Cross Competition Market Drivers of HSV Market Barriers of HSV Appendix Capabilities Contacts ResearchAndMarkets. Log In Sign Up.Based on the recent demise of experimental vaccines from Genocea and Vical the prospects for a therapeutic vaccine for genital herpes look mighty bleak at this time.
So, for most patients who need treatment valacyclovir Valtrex is the only choice 1,2. It works well for most people, but not for everyone. There has never been a therapeutic vaccine for any infectious disease, and there isn't one on the horizon. But there are plenty of drugs that work quite well for infections - antibiotics, antifungals, and antivirals. Since herpes is a viral infection is it not unrealistic to predict that an antiviral drug that works better than Valtrex could be discovered.
Based on the stunning success of antiviral drugs for treating HIV 3 and hepatitis C 4most of them coming out of the pharmaceutical industry, it is reasonable to think that this is not only possible but maybe even likely that alternative drugs could be discovered.
And one already has been. There is an alternative to Valtrex in Phase II trials right now. The drug is called pritelivir, and it is looking quite good in clinical trials. More on that later. Figure 1. Representation of how DNA polymerase works. DNA consists of a very long chain of covalently bound deoxyribose a sugar, orange circle units.
The polymerase has one function - to hook more sugars together yellow arrow. This is how the chain grows. The sugar is also bound to one of four nitrogenous bases, A, T, C, G red arrows. The bases hold serve to connect via hydrogen bonding one single strand to another to form double-stranded DNA. The newly formed bond is shown by the green line.
Source: YouTube. If you recall the early days of AIDS, the first approved drugAZT, inhibited an enzyme called reverse transcriptase, which, like acyclovir, is responsible for assembling new viral DNA. So, although the two drugs are acting on entirely different viruses, both acyclovir and AZT inhibit the same essential step in viral replication - building new genetic material so that the virus can replicate.
It was not until when Roche's Invirase was approved that there finally was a weapon against the virus - the cocktail.
By combining two or more drugs that work by different mechanisms resistance is minimized. It is much more difficult for the virus to mutate in two locations at once. All therapies consist of different drugs from different classes. This is done by an enzyme called helicase.
Figure 2. Source: Study. Just because there is no helicase inhibitor drug for HIV does not mean that the enzyme is not a valid target in other viruses.
Pritelivir works by preventing the helicase enzyme from breaking the hydrogen bonds that hold the strands together.In recent years, the threat of a viral epidemic, or even a pandemic, has become more realistic than ever before. However, besides these new threats such as MERS or Ebola virus, there are also common viral infections where either no effective or safe treatment is on the market e.
Furthermore, for many viruses e. AiCuris' mission is to identify and to develop new antivirals for such infections, that are directed not only against so-called "classical" targets e. However the past two decades have shown the celebrations to be premature.
Especially in a hospital setting, resistance to several of the most efficacious antibacterial agents has been rising constantly. Both Gram-positive and Gram-negative pathogens have collected a vast array of resistance mechanisms. Treatment failure due to antibiotic resistance is particularly grave for patients whose immune system is compromised, such as people with an underlying disease and patients in intensive care units.
According to recent health statistics, each year about 2 million people acquire bacterial infections in U. About 70 percent of these infections were caused by bacteria resistant to at least one drug. AiCuris' mission is the development of life-saving cures for the treatment of severe Gram-positive and Gram-negative infections to ensure effective antibacterial therapeutic options for the future.